Asset Details
Do you wish to reserve the book?
Talaromyces (Penicillium) marneffei infection in non-HIV-infected patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Talaromyces (Penicillium) marneffei infection in non-HIV-infected patients
Do you wish to request the book?
Talaromyces (Penicillium) marneffei infection in non-HIV-infected patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Talaromyces (Penicillium) marneffei infection in non-HIV-infected patients
2016
Overview
Talaromyces (Penicillium) marneffei is an important pathogenic thermally dimorphic fungus causing systemic mycosis in Southeast Asia. The clinical significance of T. marneffei became evident when the human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome epidemic arrived in Southeast Asia in 1988. Subsequently, a decline in the incidence of T. marneffei infection among HIV-infected patients was seen in regions with access to highly active antiretroviral therapy and other control measures for HIV. Since the 1990s, an increasing number of T. marneffei infections have been reported among non-HIV-infected patients with impaired cell-mediated immunity. Their comorbidities included primary adult-onset immunodeficiency due to anti-interferon-gamma autoantibodies and secondary immunosuppressive conditions including other autoimmune diseases, solid organ and hematopoietic stem cell transplantations, T-lymphocyte-depleting immunsuppressive drugs and novel anti-cancer targeted therapies such as anti-CD20 monoclonal antibodies and kinase inhibitors. Moreover, improved immunological diagnostics identified more primary immunodeficiency syndromes associated with T. marneffei infection in children. The higher case-fatality rate of T. marneffei infection in non-HIV-infected than HIV-infected patients might be related to delayed diagnosis due to the lack of clinical suspicion. Correction of the underlying immune defects and early use of antifungals are important treatment strategies. Clinicians should be familiar with the changing epidemiology and clinical management of T. marneffei infection among non-HIV-infected patients.
Publisher
Taylor & Francis Ltd,Nature Publishing Group,Taylor & Francis Group
Subject
/ AIDS-Related Opportunistic Infections - immunology
/ AIDS-Related Opportunistic Infections - microbiology
/ Antifungal Agents - therapeutic use
/ Asia, Southeastern - epidemiology
/ Child
/ Female
/ HIV
/ HIV Infections - microbiology
/ Human immunodeficiency virus
/ Humans
/ Male
/ Penicillium - classification
/ Penicillium - isolation & purification
/ Review
